Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-exendin PET imaging of beta cell mass after Roux-en-Y gastric bypass
2014-005554-20Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2015
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of 68Ga-NODAGA-Exendin-4 in hyperinsulinism (HI) and postprandial hypoglycemia (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Quantitative pancreatic 68Ga-NODAGA-exendin-4 uptake. Started Jul 2015; status: completed.
02
Drugs
68Ga-NODAGA-Exendin-4
03
Conditions
hyperinsulinism (HI)postprandial hypoglycemia
Beyond the preview
Go deeper on 2014-005554-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005554-20.